November Pharma and CRO Spatial Summit

  • 9:00 am - 11:00 am (PST)
Location:
Virtual

NOVEMBER 16, 9 AM PT / 12 PM ET

*A Virtual Event

Advancing Standard Tissue Analysis Practices

Don’t miss out on the opportunity to hear the first rollout of the NanoString GeoMx® DSP Best Practices Guidance as a cross-industry Pharma and CRO collaboration initiative.

The last NanoString Pharma and CRO Spatial summit focused on scaling GeoMx® workflows for large studies in biopharma. We will continue the next Summit on this topic and will hear from Contract Research Organizations (CROs), and their analytical verification approaches to support drug discovery and development studies.

If you are a current GeoMx® DSP user or are interested in learning about the execution of spatial biology studies, join us to learn more about:

  • Best practices for implementation of biopharma studies using GeoMx
  • Considerations for morphology marker and ROI selection strategies
  • Biopharma applications
  • Analytical verification studies

Program Agenda

Time (PT)SessionSpeaker
9:00 amWelcome and Introduction to GeoMxJay Clark
Senior Technical Sales Specialist
NanoString
09:20 amGeoMx Best Practices InitiativeEspy Anguiano, PhD
Scientific Market Development Director-BioPharma
NanoString
09:40 amAnalytical validation of the GeoMx Cancer Transcriptome Atlas for comprehensive spatial profiling of solid tumor samplesLakshmi Chandramohan, Ph.D.D(ABMM)
Principal Scientist and Associate Director, Molecular Assay Services, Pharma NeoGenomics Laboratories
10:00 amDigital Spatial Profiling: Transcriptional Analysis in Tumor TissuesShanshan Zhou, PhD
Manager and Lead Scientist, Molecular Pathology and Companion Diagnostics
Labcorp Drug Development
10:20 amBridging the gap between pathology image analysis and spatial transcriptomicsRegan Baird, PhD
Vice President Strategic Sales, Americas
10:40 amOptimizing Success in GeoMx Spatial Transcriptomics StudiesLester Kobzik, MD
Chief Medical Officer
Cellecta, Inc.
11:00 amPanel Discussion + Live Q&AModerated by Espy Anguiano
11:20 amClosing Remarks